At-home Drug of Abuse (DOA) Testing Market Size - By Type (Test Cups, Test Strips), By Sample Type (Saliva, Urine, Blood) & Global Forecast 2023 – 2032

At-home Drug of Abuse (DOA) Testing Market Size - By Type (Test Cups, Test Strips), By Sample Type (Saliva, Urine, Blood) & Global Forecast 2023 – 2032

At-home Drug of Abuse (DOA) Testing Market Size

At-Home Drug of Abuse Testing Market size was valued at USD 3.5 billion in 2022 and is estimated to register around 7% CAGR between 2023 and 2032. increasing production of illicit drugs will drive market growth.
 

As the prevalence of cannabis use and other illicit drugs emphasizes the need for effective preventive measures and early interventions will lead to elevated demand for drug of abuse testing. Furthermore, governments and public health authorities worldwide have been implementing various initiatives to combat drug abuse and its related consequences. These initiatives include awareness campaigns, treatment programs, and drug testing programs in workplaces and schools. The increased emphasis on drug testing has further propelled the adoption of at-home drug of abuse (DOA) testing kits as an effective tool to support these efforts.
 

COVID-19 Impact

The COVID-19 pandemic had a positive impact on the at-home drug of abuse testing market due to increased drug consumption during lockdown. The increase in consumption volumes was attributed to higher frequencies and quantities of cannabis use, with herbal cannabis being a significant contributor to this trend. This raised concerns about illicit drug abuse, leading to higher demand for at-home drug of abuse (DOA) testing kits. These kits offered a convenient and confidential way for individuals to monitor their drug use and seek timely support.
 

Growing adoption of telemedicine and virtual consultations during the pandemic further supported the integration of at-home drug of abuse (DOA) testing into remote healthcare services. Moreover, innovations in testing technology also improved the accuracy and ease of use of at-home drug of abuse (DOA) testing kits. As the pandemic situation evolved, the at-home DOA testing market continued to grow to meet the demands of individuals seeking proactive and confidential means to monitor their drug use.
 

At-Home Drug of Abuse Testing Market Trends

Advancements in diagnostic technologies have led to significant improvements in the accuracy, sensitivity, and user-friendliness of at-home drug testing kits. Manufacturers have introduced innovative testing methods, such as rapid lateral flow tests and point-of-care molecular tests, which deliver quick and reliable results. Industry participants have expanded their product portfolios to encompass a broader range of drugs, including emerging synthetic drugs. This expansion enhances the relevance and utility of at-home drug testing kits, allowing individuals to monitor a wider spectrum of substances.
 

At-Home Drug of Abuse Testing Market Analysis 

The test strips segment of at-home drug of abuse testing market surpassed USD 1.7 billion in 2022. Test strips offer quick and straightforward drug testing procedures, enabling individuals to monitor their drug use in the privacy of their homes. The rapid results provided by test strips facilitate instant feedback and timely decision-making. Despite, the widespread availability of test strips in physical stores and online platforms further contributes to their market dominance.
 

Furthermore, their versatility in detecting multiple drug classes, including opioids, cannabinoids, cocaine, and amphetamines, enhances their overall utility and appeal in addressing various drug screening needs. As the demand for at-home drug testing solutions continues to grow, test strips are anticipated to maintain their prominence as the preferred choice for proactive and reliable drug monitoring.
 

The urine segment held 38% share of the at-home drug of abuse testing market in 2022 and is poised to witness highest growth due to its practicality, ease of collection, and affordability. Urine-based testing offers a wide detection window, allowing it to detect a broad range of drugs and drug metabolites over an extended period, providing a comprehensive view of an individual's drug use history. The familiarity and acceptance of urine drug testing in various settings, along with the established regulatory framework and industry standards, contribute to its market dominance.
 

U.S. at-home drug of abuse testing market accounted for USD 1.2 billion in 2022 and is predicted to observe substantial growth.  High prevalence of drug abuse and substance use disorders in the country has led to significant demand for drug testing solutions. Additionally, with a well-established healthcare infrastructure and regulatory support, at-home drug of abuse (DOA) testing kits is readily available and compliant with stringent standards, enhancing consumer trust. The rise of telehealth and remote monitoring in the U.S. has facilitated the integration of at-home drug of abuse (DOA) testing into virtual consultations, promoting their use.
 

An initiative-taking approach to healthcare, industry innovation, and diverse drug testing needs further contribute to the popularity and dominance of the U.S. market in meeting the growing demand for accessible and effective drug monitoring solutions.
 

At-home Drug of Abuse Testing Market Share

Some of the eminent market participants operating in the at-home drug of abuse testing market include

• Abbott Laboratories
• Dragerwerk AG & Co.KGaA
• Assure Tech. (Hangzhou) Co. LTD
• Atlas Medical GmbH
• Confirm BioSciences
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Psychemedics Corporation
•  OraSure Technologies

These participants are undertaking several growth strategies including partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen their product portfolio as well as gain a competitive edge over others.
 

At-home Drug of Abuse Testing Industry News

• In February 2021, Thermo Fisher Scientific collaborated with Mindray to introduce two clinical chemistry analyzers in the U.S. and Canada. These analyzers will be accessible to customers in clinical and drug court laboratories, facilitating drug screening activities, thereby accelerating regional presence.
   

This at-home drug of abuse testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Type

• Test cups
• Test strips
• Others

By Sample Type

• Saliva
• Urine
• Blood
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • The Netherlands
  • Denmark
  • Poland
  • Sweden
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • New Zealand
  • Thailand
  • Vietnam
  • Indonesia
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Turkey